Trevi Therapeutics terminates ATM prospectus; past sales $14.6M gross

Trevi Therapeutics, Inc.

On June 2, 2025, Trevi terminated the August 15, 2023 ATM prospectus with Leerink Partners.
Sales Agreement remains in effect; no sales permitted until a new prospectus is filed.
As of March 31, 2025, Trevi sold 4,498,065 shares for gross proceeds of ~$14.6M.
No shares issued or sold under the Sales Agreement after March 31, 2025.
Commissions and fees on past sales totaled approximately $0.5M.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.